1ST Biotherapeutics, Inc.

1STBIO and LigaChemBio Form Strategic Alliance to Develop Next-Generation Oncology Therapeutics

a month ago

• 1STBIO and LigaChemBio have entered a strategic partnership to co-develop novel payloads for antibody-drug conjugates and small molecule immuno-oncology therapies over the next three years. • The collaboration aims to develop 2-4 novel drug candidates, with LigaChemBio providing initial funding and retaining exclusive licensing options for commercialization with revenue-sharing arrangements. • Building on a joint research project initiated in December 2024, the partnership leverages complementary expertise to overcome limitations of current ADC payloads and develop first-in-class oncology programs.